Management of non-small cell lung cancer has been changed dramatically since detection of EGFR mutation. The rate of EGFR mutation in East China is unknown. In China, lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality. The five-year survival rate in patients with lung cancer varies from 3.7–32.9%, depending on stage and regional differences. The majority of the tumors were Stage IIIB or IV Advanced Lung Adenocarcinoma. The two year survival rate of the patients was 70.6%, the overall survival was 58.8%. Methods: We electronically searched CNKI, Pub Med, Cochrane from database inception and manually searched Chinese-language oncology journals to identify A Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib Or Osimertinib Plus Chinese Medicine Versus Erlotinib, Gefitinib, Icotinib Or Osimertinib Alone In Patients With NSCLC, A Regional Study East China. The quality of the included trials was assessed using the method of Cochrane. If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model used. Results: Electronic database searches yielded 1450 citations with NSCLC. We identified full text articles retrieved for detailled evaluation 70. Sample size of each trial had calculated by Rev Man 5.3.
| Published in | International Journal of Clinical Oncology and Cancer Research (Volume 6, Issue 2) |
| DOI | 10.11648/j.ijcocr.20210602.14 |
| Page(s) | 74-89 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
NSCLC, EGFR Positive Mutation, Erlotinib, Gefitinib, Icotinib or Osimertinib, East China
| [1] | American Cancer Society. Lung Cancer (Non–Small Cell). Available at http://www.cancer.org/cancer/lungcancernon-smallcell/detailedguide/non-small-cell-lung-cancersurvival-rates. Updated March 4, 2015. Accessed May 19, 2015. |
| [2] | Ho C, Ramsden K, Zhai Y, et al. Less toxic chemotherapy Improves uptake of all lines of chemotherapy in advanced non–small-cell lung cancer: a 10-year retrospective population-based review. J Thorac Oncol. 2014; 9: 1180–1186. |
| [3] | Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039-49. |
| [4] | Gao G, Ren S, Li A, et al. Epidermal growth factor receptor–tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non–small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer. 2012; 131: E822–E829. |
| [5] | Kim ST, Uhm JE, Lee J, et al (2012). Randomized phase II study of gefitinib versus erlotinib in patients with advanced non small cell lung cancer who failed previous chemotherapy. Lung Cancer, 75, 82-8. |
| [6] | NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer (Version 3. 2018). |
| [7] | Cella, D., Eton, D. T., Fairclough, D. L., Bonomi, P., Heyes, A. E., Silberman, C., et al. (2002). What is a clinically meaningful change on the functional assessment of cancer therapy-lung (fact-l) questionnaire? Results from eastern cooperative oncology group (ecog) study 5592. J. Clin. Epidemiol. 55 (3), 285–295. doi: 10.1016/S0895-4356(01)00477-2. |
| [8] | Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation–positive non–small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735–742. |
| [9] | Qijin Shu (shuqjhz@163.com) Department of Medical Oncology, Integrated Chinese and Western Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 31000, P. R. China, 12. 2020. |
| [10] | S. Novello, J. Mazières, I. J. Oh et al., “Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study,” Annals of Oncology, vol. 29, no. 6, pp. 1409–1416, 2018. |
| [11] | Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009; 10 (4): 281–9. |
| [12] | S. H. Lim, J. M. Sun, S. H. Lee, J. S. Ahn, K. Park, and M. J. Ahn, “Pembrolizumab for the treatment of non-small cell lung cancer,” Expert Opinion on Biological Therapy, vol. 16, no. 3, pp. 397–406, 2016. |
| [13] | Zhang Bei, Hu Pi-li. Effect of integrated traditional Chinese and western medicine on the quality of life of cancer patients [J]. Chinese Journal of Oncology 25 (13): 98-100. Cufer T, Vrdoljak E, Gaafar R, et al (2006). |
| [14] | D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” International Journal of Surgery, vol. 8, no. 5, pp. 336–341, 2010. |
| [15] | National Center for Biotechnology Information, U.S. National Library of Medicine, Bethesda, MD, USA, 2019, https://www.ncbi.nlm.nih.gov/pubmed. |
| [16] | P. C. L., Y. F. F., H. Y., et al. Targeting PKCδ as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer. Cancer cell 2018; 34: 954–69. |
| [17] | Liu Jiaxiang. Progress in TCM treatment of lung cancer [J]. Chinese Oncology, 2002, 11 (6): 18-21. |
| [18] | Wang Xueqian, Zhang Ying, Liu Jie, Et al. Randomized controlled study of self-made rash granules in treating EGFR-TKI related rash [J]. World Journal of Integrated Traditional Chinese and Western Medicine, 2016, 11 (12): 1629-1632. |
| [19] | Zhejiang Chinese Medical University, S. J. L.. Study on the effect and dynamic changes of syndrome of TCM of Traditional Chinese Medicine combined with Icotinib in treatmeng of advanced NSCLC. 2015. |
| [20] | Li, S. G., Chen, H. Y., Ou-Yang, C. S., Wang, X. X., Yang, Z. J., Tong, Y., et al. (2013). The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 8 (2), e57604. doi: 10.1371/journal.pone.0057604. |
| [21] | Wang, Q., Jiao, L., Wang, S., Chen, P., Bi, L., Zhou, D., et al. (2018). Maintenance chemotherapy with chinese herb medicine formulas vs. with placebo in patients with advanced non-small cell lung cancer after first-line chemotherapy: a multicenter, randomized, double-blind trial. Front. Pharmacol. 9, 1233. doi: 10.3389/fphar.2018.01233. |
| [22] | Chan A, Tan HL, Ching TH, Tan HC. Clinical outcomes for cancer patients using complementary and alternative medicine. Altern Ther Health Med. 2012; 18 (1): 12–7. |
| [23] | Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 2005; 23 (1): 165–74. |
| [24] | Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15 (16): 5267–73. |
| [25] | E. Giovannetti, P. A. Zucali, G. J. Peters et al., “Association of polymorphisms in AKT1 and EGFR with clinical outcome and Journal of Oncology 13toxicity in non-small cell lung cancer patients treated with gefitinib,” Molecular Cancer: erapeutics, vol. 9, no. 3, pp. 581–593, 2010. |
| [26] | J. P. A. Ioannidis and T. A. Trikalinos, “'e appropriateness of asymmetry tests for publication bias in meta-analyses: a largesurvey,” Canadian Medical Association Journal, vol. 176, no. 8, pp. 1091–1096, 2007. |
APA Style
Kayembe Mwimbi David, Gaochenxi Zhang, Zaiwei Huang, Ying Wang, Wenpei Zhu, et al. (2021). Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib or Osimertinib Plus Chinese Medicine Versus EGFRTKIs Alone In Patients With NSCLC, A Regional Study East China. International Journal of Clinical Oncology and Cancer Research, 6(2), 74-89. https://doi.org/10.11648/j.ijcocr.20210602.14
ACS Style
Kayembe Mwimbi David; Gaochenxi Zhang; Zaiwei Huang; Ying Wang; Wenpei Zhu, et al. Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib or Osimertinib Plus Chinese Medicine Versus EGFRTKIs Alone In Patients With NSCLC, A Regional Study East China. Int. J. Clin. Oncol. Cancer Res. 2021, 6(2), 74-89. doi: 10.11648/j.ijcocr.20210602.14
AMA Style
Kayembe Mwimbi David, Gaochenxi Zhang, Zaiwei Huang, Ying Wang, Wenpei Zhu, et al. Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib or Osimertinib Plus Chinese Medicine Versus EGFRTKIs Alone In Patients With NSCLC, A Regional Study East China. Int J Clin Oncol Cancer Res. 2021;6(2):74-89. doi: 10.11648/j.ijcocr.20210602.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcocr.20210602.14,
author = {Kayembe Mwimbi David and Gaochenxi Zhang and Zaiwei Huang and Ying Wang and Wenpei Zhu and Dan Wang and Mwema Ngoy Gracia and Wang Hong and Liang Yi and Shuyi Chen and Chen Huihui and Qijin Shu},
title = {Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib or Osimertinib Plus Chinese Medicine Versus EGFRTKIs Alone In Patients With NSCLC, A Regional Study East China},
journal = {International Journal of Clinical Oncology and Cancer Research},
volume = {6},
number = {2},
pages = {74-89},
doi = {10.11648/j.ijcocr.20210602.14},
url = {https://doi.org/10.11648/j.ijcocr.20210602.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20210602.14},
abstract = {Management of non-small cell lung cancer has been changed dramatically since detection of EGFR mutation. The rate of EGFR mutation in East China is unknown. In China, lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality. The five-year survival rate in patients with lung cancer varies from 3.7–32.9%, depending on stage and regional differences. The majority of the tumors were Stage IIIB or IV Advanced Lung Adenocarcinoma. The two year survival rate of the patients was 70.6%, the overall survival was 58.8%. Methods: We electronically searched CNKI, Pub Med, Cochrane from database inception and manually searched Chinese-language oncology journals to identify A Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib Or Osimertinib Plus Chinese Medicine Versus Erlotinib, Gefitinib, Icotinib Or Osimertinib Alone In Patients With NSCLC, A Regional Study East China. The quality of the included trials was assessed using the method of Cochrane. If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model used. Results: Electronic database searches yielded 1450 citations with NSCLC. We identified full text articles retrieved for detailled evaluation 70. Sample size of each trial had calculated by Rev Man 5.3.},
year = {2021}
}
TY - JOUR T1 - Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib or Osimertinib Plus Chinese Medicine Versus EGFRTKIs Alone In Patients With NSCLC, A Regional Study East China AU - Kayembe Mwimbi David AU - Gaochenxi Zhang AU - Zaiwei Huang AU - Ying Wang AU - Wenpei Zhu AU - Dan Wang AU - Mwema Ngoy Gracia AU - Wang Hong AU - Liang Yi AU - Shuyi Chen AU - Chen Huihui AU - Qijin Shu Y1 - 2021/05/15 PY - 2021 N1 - https://doi.org/10.11648/j.ijcocr.20210602.14 DO - 10.11648/j.ijcocr.20210602.14 T2 - International Journal of Clinical Oncology and Cancer Research JF - International Journal of Clinical Oncology and Cancer Research JO - International Journal of Clinical Oncology and Cancer Research SP - 74 EP - 89 PB - Science Publishing Group SN - 2578-9511 UR - https://doi.org/10.11648/j.ijcocr.20210602.14 AB - Management of non-small cell lung cancer has been changed dramatically since detection of EGFR mutation. The rate of EGFR mutation in East China is unknown. In China, lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality. The five-year survival rate in patients with lung cancer varies from 3.7–32.9%, depending on stage and regional differences. The majority of the tumors were Stage IIIB or IV Advanced Lung Adenocarcinoma. The two year survival rate of the patients was 70.6%, the overall survival was 58.8%. Methods: We electronically searched CNKI, Pub Med, Cochrane from database inception and manually searched Chinese-language oncology journals to identify A Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib Or Osimertinib Plus Chinese Medicine Versus Erlotinib, Gefitinib, Icotinib Or Osimertinib Alone In Patients With NSCLC, A Regional Study East China. The quality of the included trials was assessed using the method of Cochrane. If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model used. Results: Electronic database searches yielded 1450 citations with NSCLC. We identified full text articles retrieved for detailled evaluation 70. Sample size of each trial had calculated by Rev Man 5.3. VL - 6 IS - 2 ER -
Information
Email: